Showing 6991-7000 of 9343 results for "".
2017 Tax Cuts and Jobs Act: What You Need to Know
https://practicaldermatology.com/topics/practice-management/2017-tax-cuts-and-jobs-act-what-you-need-to-know--vmyiwowa/18348/OJM Group principal Carole Foos, CPA provides an overview of the Tax Cuts and Jobs Act, which was signed in to law at the end of 2017. She discusses key provisions affecting individual physicians and medical practices, and offers advice to consider when planning for 2018 and beyond. Click here to reGo Big or Go Home? Taking MIPS to The Max
https://practicaldermatology.com/topics/practice-management/go-big-or-go-home-taking-mips-to-the-max/20696/Part three in a three-part series on the MIPS “pick-your-pace” transition.Itch Be Gone
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/itch-be-gone/18524/Could botulinum toxins be the answer for non-histaminergic itch? Erin Gilbert, MD discusses her research in this area and results she's seen to date.Enbrel Gets Nod for Pediatric PsO; IL-33 Targeted in Itch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-enbrel-gets-nod-for-pediatric-pso-il-33-targeted-in-itch/18562/FDA approved Amgen's Enbrel (etanercept) for chronic moderate to severe psoriasis in pediatric patients age 4 to 17. DermCheck App partners with anti-bullying groups Pacer and Not In My Town to help fight bullying and expand acne care. Researchers show that anti-IL-33 antibody reduces itch of poisonAllergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National PsoriasisCurrents: Think Big
https://practicaldermatology.com/topics/skin-cancer-photoprotection/currents-think-big/20893/Big picture approaches can unlock new solutions to dermatologic diseases.Improving Outcomes with Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/improving-outcomes-with-fillers/18740/For the most optimal outcomes when injecting fillers, Dr. Galadari says there are three essential steps: choose the right patient, choose the right filler, and choose the right injection technique. He shares his favorite types of fillers for specific areas and discusses when and why he uses a cannulUgh, I've Been Yelp'd!
https://practicaldermatology.com/topics/practice-management/ugh-ive-been-yelpd/21102/Clinicians bugged by powerful review sites should know physicians have options.Restylane Lyft Approved, Analyzing New Quality of Life Data
https://practicaldermatology.com/series/dermwire-tv/dermwire-restylane-lyft-approved-analyzing-new-quality-of-life-data--ibalorid/18878/Restylane Lyft from Galderma approved for mid face volume enhancement, New data analyzes significance of patient quality of life in diseases like psoriasis and atopic dermatitis, Merz North America establishes new headquarters in Raleigh, NC, and Boston unveils free sunscreen dispensers.Radiesse for Hands, Alevicyn Cleared
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-radiesse-for-hands-alevicyn-cleared/18898/Merz gets FDA approval for Radiesse for hand augmentation and releases data comparing Xeomin to Botox. Heidi Waldorf, MD, FAAD and Michael Gold, MD, FAAD, comment. Also in this edition, Galderma participate in a White House forum on antibiotic stewardship, and the FDA gives 510(k) clearance to Alevi